Name

Hameln Pharma Ltd

Legal name

hameln pharma gmbh

Website

https://hameln.co.uk

Company type

Private

Founded year

1890

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Headquarters

HQ city

Hameln

HQ country

Germany

HQ region

Europe

Offices9 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Generic Injectable Medicines Sales: Sale of generic injectable pharmaceutical products including analgesics, anesthetics, sedatives, antiemetics, antidotes, opioids, and critical care products to hospitals, pharmacies, and healthcare facilities globally.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Hameln Pharma Ltd is a fourth-generation owner-managed pharmaceutical group that develops, licenses, manufactures, and markets generic injectable medicines, including analgesics, anesthetics, sedatives, antiemetics, antidotes, opioids, and critical care products. The company delivers more than 140 million doses per year across 65+ active ingredients to hospitals, pharmacies, outpatient surgery centres, medical practices, and palliative care centres in more than 45 countries through nine wholly owned subsidiary companies.

Product overview

Hameln Pharma Ltd operates as a single unified portfolio of generic injectable medicines with supporting product lines. The core offering comprises a broad portfolio of generic injectable medicines spanning analgesics, anesthetics, sedatives, antiemetics, antidotes, opioids, and critical care products. This portfolio is supported by three named product/service offerings: Ready-to-Use Products with Integrated Syringe Label® (pre-filled syringes with integrated labeling for clinical efficiency), Intelligent Packaging Design (proprietary packaging solutions for safety and usability), and Robust Supply Chain (logistics services for global distribution). The company delivers more than 140 million doses annually across 65+ active ingredients in 45+ countries, positioning the injectable medicines portfolio as the central platform with specialized packaging and supply chain services as complementary capabilities.

Differentiator

Problem solved

Functional benefit

Products and services

• Generic Injectable Medicines Portfolio Broad range of generic injectable medicines covering analgesics, anesthetics, sedatives, antiemetics, antidotes, opioids, and critical care products used in hospitals, pharmacies, outpatient surgery centres, and palliative care settings.
• Ready-to-Use Products with Integrated Syringe Label Pre-filled syringes and ready-to-administer injectable products featuring an integrated syringe label designed to improve preparation efficiency and reduce medication errors in clinical settings.
• Intelligent Packaging Design Proprietary packaging solutions designed to enhance safety, usability, and efficiency in the handling and administration of injectable medicines.

Quantifiable outcome

• Over 140 million doses delivered to customers in 2024
• +2 more outcomes

Segments5 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Sun Pharmaceutical Industries: Indian-headquartered global generics manufacturer with sterile injectables in its portfolio. Less concentrated in injectables than Hameln, but competes for hospital tenders in overlapping markets.
• Viatris: Global generics and specialty company formed from Mylan and Upjohn, with injectable products serving hospital and surgical markets. Overlaps with Hameln in hospital-channel generic injectables but operates with much greater therapeutic and geographic breadth.
• Sandoz: Global generics leader and Novartis spin-off with a sizable sterile injectable franchise across antibiotics, oncology, and hospital injectables. Overlaps with Hameln in generic injectables for hospitals but operates at significantly larger scale and breadth.
• Teva Pharmaceutical Industries: One of the world's largest generic drug manufacturers with a meaningful injectable portfolio serving hospitals. Competes with Hameln in tender-based generic injectable markets but is far broader in scope (oral solids, biosimilars, APIs).
• Pfizer CentreOne (Hospira heritage): Pfizer's injectables business, built on the Hospira acquisition, supplies a broad hospital injectable portfolio including analgesics and anesthesia adjacents. Competes with Hameln in the same hospital channels but at much larger scale and broader therapeutic depth.

Direct peers

• Aurobindo Pharma: Indian-headquartered generic pharmaceutical manufacturer with a growing sterile injectables business supplying regulated markets including Europe. Comparable to Hameln in targeting generic injectable tenders and hospital accounts.
• Fresenius Kabi: German-headquartered global supplier of generic injectable medicines, IV drugs, and clinical nutrition to hospitals. Directly comparable to Hameln in therapeutic focus, customer base (hospitals), and reliance on tender-based generic injectable distribution.
• B. Braun: German medical and pharmaceutical company with a major sterile injectable and infusion solutions business serving hospitals globally. Closely matches Hameln on geography of origin, injectable expertise, and hospital-channel distribution model.
• Hikma Pharmaceuticals: Specialty generic injectable manufacturer with strong hospital channel presence across Europe, MENA, and the US. Comparable to Hameln in portfolio breadth (anesthetics, analgesics, critical care injectables) and contract/tender-driven sales.
• Dr. Reddy's Laboratories: Indian generics company with a focused sterile injectables portfolio (anesthetics, oncology injectables) sold into European and emerging markets. Comparable to Hameln in therapeutic mix and regulatory-driven hospital sales.

Market position

Strengths1 record

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/hameln-pharma-ltd

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Hameln Pharma Ltd